白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2012年
9期
524-527
,共4页
朱坚轶%陈芳源%肖菲%黄洪晖%钟华%韩晓凤%王婷%徐岚%钟璐%倪蓓文
硃堅軼%陳芳源%肖菲%黃洪暉%鐘華%韓曉鳳%王婷%徐嵐%鐘璐%倪蓓文
주견질%진방원%초비%황홍휘%종화%한효봉%왕정%서람%종로%예배문
淋巴瘤,B细胞%利妥昔单抗%乙型肝炎病毒%再激活%拉米夫定
淋巴瘤,B細胞%利妥昔單抗%乙型肝炎病毒%再激活%拉米伕定
림파류,B세포%리타석단항%을형간염병독%재격활%랍미부정
Lymphoma,B-cell%Rituximab%Hepatitis B virus%Reactivation%Lamivudine
目的 研究利妥昔单抗联合化疗治疗B细胞非霍奇金淋巴瘤( B-NHL)合并乙型肝炎病毒( HBV)携带患者的安全性,探讨拉米夫定预防性治疗的价值.方法 回顾性分析含利妥昔单抗联合化疗前后B-NHL患者乙型肝炎五项、HBV-DNA和肝功能指标变化.将39例HBV核心抗体(HBcAb)(+)/HBV表面抗体(HBsAb)(-)的B-NHL患者分为拉米夫定预防组和对照组,比较两组化疗后HBV再激活、肝功能损害等指标.结果 108例接受利妥昔单抗联合化疗的B-NHL患者中,15例患者为HBV表面抗体(HBsAg)(+),占所有患者的13.89 ％;39例为HBsAg(-)/HBcAb(+)患者,占所有患者的36.11％.15例HBsAg(+)的患者中HBV再激活率为13.3％,13例拉米夫定预防患者中1例(7.7％)HBV再激活,2例未预防的患者中1例HBV再激活.39例HBsAg(-)/HBcAb(+)患者中HBV再激活率为7.7％(3例),14例拉米夫定预防组HBV再激活率为0,25例未预防的患者中3例(12％)HBV再激活.结论 B-NHL合并HBV携带患者在利妥昔单抗联合化疗导致HBV再激活的风险是可控的,预防性使用拉米夫定能明显降低HBV再激活.
目的 研究利妥昔單抗聯閤化療治療B細胞非霍奇金淋巴瘤( B-NHL)閤併乙型肝炎病毒( HBV)攜帶患者的安全性,探討拉米伕定預防性治療的價值.方法 迴顧性分析含利妥昔單抗聯閤化療前後B-NHL患者乙型肝炎五項、HBV-DNA和肝功能指標變化.將39例HBV覈心抗體(HBcAb)(+)/HBV錶麵抗體(HBsAb)(-)的B-NHL患者分為拉米伕定預防組和對照組,比較兩組化療後HBV再激活、肝功能損害等指標.結果 108例接受利妥昔單抗聯閤化療的B-NHL患者中,15例患者為HBV錶麵抗體(HBsAg)(+),佔所有患者的13.89 ％;39例為HBsAg(-)/HBcAb(+)患者,佔所有患者的36.11％.15例HBsAg(+)的患者中HBV再激活率為13.3％,13例拉米伕定預防患者中1例(7.7％)HBV再激活,2例未預防的患者中1例HBV再激活.39例HBsAg(-)/HBcAb(+)患者中HBV再激活率為7.7％(3例),14例拉米伕定預防組HBV再激活率為0,25例未預防的患者中3例(12％)HBV再激活.結論 B-NHL閤併HBV攜帶患者在利妥昔單抗聯閤化療導緻HBV再激活的風險是可控的,預防性使用拉米伕定能明顯降低HBV再激活.
목적 연구리타석단항연합화료치료B세포비곽기금림파류( B-NHL)합병을형간염병독( HBV)휴대환자적안전성,탐토랍미부정예방성치료적개치.방법 회고성분석함리타석단항연합화료전후B-NHL환자을형간염오항、HBV-DNA화간공능지표변화.장39례HBV핵심항체(HBcAb)(+)/HBV표면항체(HBsAb)(-)적B-NHL환자분위랍미부정예방조화대조조,비교량조화료후HBV재격활、간공능손해등지표.결과 108례접수리타석단항연합화료적B-NHL환자중,15례환자위HBV표면항체(HBsAg)(+),점소유환자적13.89 ％;39례위HBsAg(-)/HBcAb(+)환자,점소유환자적36.11％.15례HBsAg(+)적환자중HBV재격활솔위13.3％,13례랍미부정예방환자중1례(7.7％)HBV재격활,2례미예방적환자중1례HBV재격활.39례HBsAg(-)/HBcAb(+)환자중HBV재격활솔위7.7％(3례),14례랍미부정예방조HBV재격활솔위0,25례미예방적환자중3례(12％)HBV재격활.결론 B-NHL합병HBV휴대환자재리타석단항연합화료도치HBV재격활적풍험시가공적,예방성사용랍미부정능명현강저HBV재격활.
Objective To investigate the safety of rituximab combination chemotherapy in the treatment of B-cell non-Hodgkin' s lymphoma (B-NHL) complicated with hepatitis B virus (HBV) infection,and assess the incidence of HBV reactivation reduced by prophylactic lamivudine.Methods A retrospective study of HBV-related markers,HBV-DNA and liver function was performed before and after rituximabcontaining treatment in B-NHL patients.Thirty nine B-NHL patients with HBcAb(+)/HBsAb(-) were divided into prophylactic group (14 cases) and control group (25 cases).The incidences of HBV reactivation,functional damage of liver were measured.Results Among the 108 B-NHL patients who received rituximab combinatio nchemotherapy,15 (13.89 ％) were HBsAg (+) and 39 (36.11％) HBsAg (-) / HBcAb (+).Of the 15 HBsAg (+)patients,2 (13.3 ％) experienced reactivation of HBV.The prevalence of HBV reactivation was 7.7 ％(1/13) in patients who received prophylactic antiviral treatment and 50 ％ (1/2) in those who did not receivelamivudine.Among the 39 HBsAg (-) / HBcAb (+) patients,3 cases (7.7 ％) experienced reactivation of HBV.The prevalence of HBV reactivation was 0 in patients who receivcd prophylactic lamivudine treatment and 12 ％ (3/25) in those who did not receive this antiviral drug.Conclusion Prophylactic lamivudine before rituximab combination chemotherapy can reduce HBV reactivation obviously.
